Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis

Bibliographic Details

Main Authors:	Lindner, Samuel M. (Author) , Hacke, Werner (Author)
Format:	Article (Journal)
Language:	English
Published:	March 6, 2017
In:	Circulation Year: 2017, Volume: 135, Issue: 10, Pages: 1001-1003
ISSN:	1524-4539
DOI:	10.1161/CIRCULATIONAHA.116.024666
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1161/CIRCULATIONAHA.116.024666
Author Notes:	Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators